At the news
? BEARISHIMPACT 6/10 6-K filed Sep 4, 2026 at 17:22 ET
Novartis announced that its Phase III Lp(a)HORIZON trial for pelacarsen, an investigational antisense oligonucleotide targeting elevated lipoprotein(a), did not meet the primary endpoint of reducing cardiovascular events in patients with elevated Lp(a) and established CVD. Despite achieving lower Lp(a) levels, the drug failed to translate biomarker reduction into clinical benefit, eliminating a major pipeline opportunity in a large unmet cardiovascular market.
- Pelacarsen Phase III Lp(a)HORIZON trial (NCT04023552) did not meet its primary composite endpoint of cardiovascular death, non-fatal MI, non-fatal stroke, and urgent coronary revascularization requiring hospitalization.
- Trial enrolled 8,323 patients with elevated Lp(a) (≥70 mg/dL) and established CVD; lower Lp(a) levels were achieved but did not reduce cardiovascular risk.
- Novartis obtained global rights to pelacarsen under a license and collaboration agreement with Ionis Pharmaceuticals.
- Elevated Lp(a) affects approximately 20% of the global population with no approved targeted treatment.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access